Inhibitor of binding of S1P 1

Details Inhibitor of binding of S1P 1 Inhibitor of binding of S1P 1

2008-08-01

2011-11-01

Kosack, Joseph (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S253120, C514S235500, C514S307000, C514S314000, C546S300000, C546S148000, C546S167000, C544S365000, C544S124000, C544S131000

Reexamination Certificate

active

08048898

ABSTRACT:
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof:(wherein Y1represents a nitrogen atom or a group represented by CRA, Y2represents a nitrogen atom or a group represented by CRB, Y3represents a nitrogen atom or a group represented by CRC, RA, RBand RC, which may be the same or different, each represent a hydrogen atom, etc. (excluding the case where Y1is CRA, Y2is CRBand Y3is CRC), X represents an oxygen atom, etc., R1represents a C1-C6alkyl group, etc., R2represents a C1-C6alkyl group, etc., R3represents an optionally substituted phenyl group, etc., R4represents a hydrogen atom, etc., and R5represents an optionally substituted phenyl group, etc.) has an inhibitory effect on the binding between S1P and its receptor Edg-1(S1P1), and is useful as a therapeutic agent for autoimmune diseases, rheumatoid arthritis, asthma, atopic dermatitis, rejection after organ transplantation, cancer, retinopathy, psoriasis, osteoarthritis, or age-related macular degeneration, etc.

REFERENCES:
patent: 5516783 (1996-05-01), Whittaker et al.
patent: 5910506 (1999-06-01), Sugimoto et al.
patent: 2003/0229125 (2003-12-01), Haaf et al.
patent: 2005/0124654 (2005-06-01), Groneberg et al.
patent: 2007/0232682 (2007-10-01), Beard et al.
patent: 2009/0131438 (2009-05-01), Ono et al.
patent: 2010/0041655 (2010-02-01), Ono et al.
patent: 0786455 (1997-07-01), None
patent: 1798226 (2007-06-01), None
patent: 5-194412 (1993-08-01), None
patent: 2002-212070 (2002-07-01), None
patent: 2002-332278 (2002-11-01), None
patent: 2003-137894 (2003-05-01), None
patent: 2003/530388 (2003-10-01), None
patent: 2004/532276 (2004-10-01), None
patent: 96/10019 (1996-04-01), None
patent: 01/77089 (2001-10-01), None
patent: 02/18395 (2002-03-01), None
patent: 02/100853 (2002-12-01), None
patent: 03/000679 (2003-01-01), None
patent: 03/073986 (2003-09-01), None
patent: 03/074008 (2003-09-01), None
patent: 03/097028 (2003-11-01), None
patent: 03/105771 (2003-12-01), None
patent: 2004/024673 (2004-03-01), None
patent: 2004/074257 (2004-09-01), None
patent: 2004/089367 (2004-10-01), None
patent: 2004/103279 (2004-12-01), None
patent: 2005/123677 (2005-12-01), None
patent: 2006/013948 (2006-02-01), None
patent: 2006/097489 (2006-09-01), None
patent: WO 2006097489 (2006-09-01), None
patent: 2007/083089 (2007-07-01), None
patent: 2007/091570 (2007-08-01), None
patent: 2007/112322 (2007-10-01), None
patent: 2007/122401 (2007-11-01), None
patent: 2007/129019 (2007-11-01), None
Extended European Search Report issued Nov. 23, 2010 from the European Patent Office in a counterpart European Application No. 07713881.6 of the co-pending U.S. Appl. No. 12/278,477.
Gehlen, H., et al., ′2-Amino-1,3,4-oxadiazoles. IX. Oxidation of Aldehyde Semicarbazones to 2-amino-1, 3,4-oxadiazoles and Their Conversion Into 1-acylsemicarbazides, Justus Liebigs Annalen Der Chemi, vol. 651, pp. 133-136, 1962.
International Search Report for International Application No. PCT/JP2008/063851, dated Sep. 22, 2008.
Gehlen et al., “2-Amino-1,3,4-oxadiazoles. VIII. Formation of 2-amino-5-aminoalkyl-1,3,4-oxadiazoles and their conversion into 1,2,4-triazoles and triazolones”, Justus Liebigs Annalen der Chemie, Paedagogischen Hochschule, English language STN Abstract, vol. 651, pp. 128-132, 1962.
Von Heinz Gehlen, et al; Zur Kenntnis der 2-Amino-1,3,4-oxdiazole, X, “3-Alkoxy-1,2,4-Triazole Durch Alkoholyse von 2-Amino-1,3,4-Oxdiazolen”, Liebigs Ann. Chem., vol. 651, pp. 137-141 (with an English translation), 1962.
M. Germana Sanna et al., “Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate”, The Journal of Biological Chemistry, vol. 279, No. 14, Issue of Apr. 2, pp. 13839-13848, 2004.
Jeremy J. Clemens et al., “Synthesis of Para-Alkyl Aryl Amide Analogues of Sphingosine-1-phosphate: Discovery of Potent S1P Receptor Agonists”, Bioorganic & Medicinal Chemistry Letters, vol. 13, pp. 3401-3404, 2003.
Guofeng Jia, et al., “Syntheses of Some New 4-Amino-5-(N-methyl-arylsulfonamido)methyl-1,2,4-triazole-3-thiones and Their Derivatives”, Heteroatom Chemistry, vol. 7, No. 4, pp. 263-267, 1996.
Supplemental European Search Report dated Oct. 13, 2009, issued in European Application No. 07708069.5.
James R. Van Brocklyn et al., Sphingosine-1-phosphate stimulates motility and invasiveness of human glioblastoma multiforme cells, Cancer Letters, Elsevier, 2003, pp. 53-60, vol. 199.
Zdzislaw Brzozowski, 2-Mercapto-N-(Azolyl) Benzenesulphonamides I. Synthesis of N-(1,1-Dioxo-1,4,2-Benzodithianzin-3-YL)Guanidines and Their Transformations Into 2-Mercapto-N-(5-Amino-1,2,4-Triazol-3-YL) Benzenesulphonamide Dervatives with Potential Anti-HIV or Anticancer Activity, Department of Drug Technology, Faculty of Pharmacy, School of Medicine, Acta Poloniae Pharmaceutica-Drug Research, Polish Pharmaceutical Society, 1995, pp. 91-101, vol. 52, No. 2.
Timothy Hla, Physiological and Pathological Actions of Sphingosine 1-Phosphate, 15 Sem. Cell & Dev. Bio., 513 (2004).

Affiliated with

Also associated with

Rating

Inhibitor of binding of S1P 1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitor of binding of S1P 1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitor of binding of S1P 1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4279297